Search by Drug Name or NDC
NDC 61703-0326-18 Pamidronate Disodium 9 mg/mL Details
Pamidronate Disodium 9 mg/mL
Pamidronate Disodium is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Hospira, Inc.. The primary component is PAMIDRONATE DISODIUM.
MedlinePlus Drug Summary
Pamidronate is used to treat high levels of calcium in the blood that may be caused by certain types of cancer. Pamidronate is also used along with cancer chemotherapy to treat bone damage caused by multiple myeloma (cancer that begins in the plasma cells [a type of white blood cell that produces substances needed to fight infection]) or by breast cancer that has spread to the bones. Pamidronate is also used to treat Paget's disease (a condition in which the bones are soft and weak and may be deformed, painful, or easily broken). Pamidronate injection is in a class of medications called bisphosphonates. It works by slowing bone breakdown, increasing bone density (thickness) and decreasing the amount of calcium released from the bones into the blood.
Related Packages: 61703-0326-18Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Pamidronate Injection
Product Information
| NDC | 61703-0326 |
|---|---|
| Product ID | 61703-326_f19fc8a2-98f0-478c-8063-0596852cfccb |
| Associated GPIs | 30042060102012 |
| GCN Sequence Number | 047041 |
| GCN Sequence Number Description | pamidronate disodium VIAL 90 MG/10ML INTRAVEN |
| HIC3 | P4L |
| HIC3 Description | BONE RESORPTION INHIBITORS |
| GCN | 85999 |
| HICL Sequence Number | 006250 |
| HICL Sequence Number Description | PAMIDRONATE DISODIUM |
| Brand/Generic | Generic |
| Proprietary Name | Pamidronate Disodium |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | PAMIDRONATE DISODIUM |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 9 |
| Active Ingredient Units | mg/mL |
| Substance Name | PAMIDRONATE DISODIUM |
| Labeler Name | Hospira, Inc. |
| Pharmaceutical Class | Bisphosphonate [EPC], Diphosphonates [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA075841 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 61703-0326-18 (61703032618)
| NDC Package Code | 61703-326-18 |
|---|---|
| Billing NDC | 61703032618 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (61703-326-18) / 10 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2005-10-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |